DataM Intelligence | competitive Intelligence ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

Back in 2019, the companies teamed up to develop a successor to their multiple myeloma blockbuster Darzalex, an anti-CD38 antibody. The deal gave J&J the option to license HexaBody-CD38—which ...

Sarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple ...

With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU. Olivier Nataf, global head of oncology at Sanofi, said: ...